Thu, Oct 23, 2014, 2:05 AM EDT - U.S. Markets open in 7 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

btrav1752 6 posts  |  Last Activity: Oct 14, 2014 11:58 AM Member since: May 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CPRX analysts comical price projections

    by bigredwf Oct 13, 2014 10:18 AM
    btrav1752 btrav1752 Oct 14, 2014 11:58 AM Flag

    Don't you ever get tired of being wrong?

  • Reply to

    I'll TRY to post this.Yahoo sucks

    by btrav1752 Oct 23, 2013 11:31 AM
    btrav1752 btrav1752 Oct 23, 2013 11:42 AM Flag

    Blemish on a Strong Year
    Friday’s plunge comes amid a strong year for Catalyst, that saw the stock gain nearly 680 percent from January 1 by the time it hit its 52-week high on October 3. The company’s run, though, has been driven in large part by the potential of Firdapse. The sharp downward move also comes just two days after Roth Capital raised their price target for the stock to $3.75 a share. After today’s drop, shares are trading at just under $2.

  • Reply to

    I'll TRY to post this.Yahoo sucks

    by btrav1752 Oct 23, 2013 11:31 AM
    btrav1752 btrav1752 Oct 23, 2013 11:37 AM Flag

    They'll let us post if it's part of a AF article but not anything that is in favor of the company.

  • Reply to

    I'll TRY to post this.Yahoo sucks

    by btrav1752 Oct 23, 2013 11:31 AM
    btrav1752 btrav1752 Oct 23, 2013 11:33 AM Flag

    This is off of Equities.

  • Reply to

    I'll TRY to post this.Yahoo sucks

    by btrav1752 Oct 23, 2013 11:31 AM
    btrav1752 btrav1752 Oct 23, 2013 11:32 AM Flag

    Firdapse Not the Only LEMS Treatment
    The most damning allegation included in Feuerstein’s article was that a private, family-owned pharmaceutical company, Jacobus Pharmaceuticals, manufactures and distributes a drug called 3,4-dap for treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) – a rare neuromuscular disease that leads to progressive muscle weakness and affects only a few thousand Americans a year – at no cost. This is trouble for Catalyst, which is currently seeking orphan drug status for Firdapse, another drug that treats LEMS. Firdapse is already being used to treat LEMS in Europe and Catalyst had licensed it from Biomarin Pharmaceuticals (BMRN) , its European distributor, for use in the United States. They’re currently seeking FDA approval for the drug and, should the current Phase III clinical trial return positive results, the company is anticipating a approval in 2015 and to begin selling in 2016.
    But 3,4-Dap has been available for decades and is an equivalent drug to Firdapse, undercutting the potential for tremendous profits for Catalyst. Catalyst anticipates charging about $60,000 a year for Firdapse treatment, so Feuerstein’s revelation could be potentially damning.
    Blemish on a Strong Year
    Friday’s plunge comes amid a strong year for Catalyst, that saw the stock gain nearly 680 percent from January 1 by the time it hit its 52-week high on October 3. The company’s run, though, has been driven in large part by the potential of Firdapse. The sharp downward

  • Shares in small-cap biopharmaceutical company Catalyst Pharmaceutical Partners (CPRX) tumbled sharply Friday morning on heavy volume. Catalyst's stock opened down 21.5 percent, saw losses reach 34.5 percent by mid-morning, and remained off just under 25 percent by early afternoon. There was no immediately apparent reason for the major sell-off, which saw volume nearing 8 million shares as compared to an average daily volume of about 2.5 million, except for an article by analyst Adam Feuerstein.
    Firdapse Not the Only LEMS Treatment

AFFY
0.120.00(0.00%)Oct 22 1:51 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.